LMO4 Inhibitors
The chemical class termed LMO4 inhibitors encompasses a diverse group of compounds that indirectly modulate the activity of the LIM domain only 4 (LMO4) protein. These inhibitors do not act directly on LMO4 but influence various signaling pathways and cellular processes that are integral to LMO4's functional regulation. This indirect mode of action is crucial as direct inhibitors of LMO4 are not available, necessitating the targeting of interconnected pathways to achieve desired modulatory effects on LMO4. The primary focus of LMO4 inhibitors is on pathways involved in cellular differentiation, proliferation, and metabolic regulation. These include the PI3K/AKT, MAPK/ERK, JAK-STAT, Notch, Hedgehog, Wnt/β-Catenin, NF-κB, TGF-β, AMPK, calcium signaling, PKC, and GSK-3β pathways. Each inhibitor in this class acts on a specific target within these pathways, leading to a cascade of events that ultimately influence LMO4 activity. For instance, PI3K inhibitors like Wortmannin disrupt the PI3K/AKT pathway, thereby impacting cellular processes that LMO4 regulates. Similarly, inhibitors targeting the MAPK/ERK pathway, such as U0126, affect the phosphorylation of key enzymes, indirectly modulating LMO4's involvement in cell growth and differentiation.
The significance of LMO4 inhibitors lies in their ability to modulate a transcriptional regulator that plays a pivotal role in various biological processes. By targeting pathways that intersect with LMO4's regulatory network, these inhibitors provide a means to influence LMO4 activity indirectly. This approach is essential for studying LMO4's role in cellular processes and for investigating the molecular mechanisms underlying its regulation. The diverse nature of these inhibitors reflects the complexity of the signaling networks in which LMO4 operates, underscoring the intricacy of targeting such a multifaceted protein.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a phosphatidylinositol 3-kinase (PI3K) inhibitor, disrupts the PI3K/AKT signaling pathway, crucial for cellular proliferation and survival. Its inhibition can indirectly influence LMO4 activity, as LMO4 is involved in related cellular differentiation and proliferation processes. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42, a tyrosine kinase inhibitor, targets JAK2/STAT3 signaling. Disruption of cytokine signaling and cellular growth mechanisms by inhibiting this pathway indirectly influences LMO4's role in cell proliferation and differentiation. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $99.00 $335.00 $836.00 $2099.00 | 47 | |
DAPT, a gamma-secretase inhibitor, blocks Notch receptor cleavage, inhibiting the Notch signaling pathway, crucial for cell fate determination. Alterations in Notch signaling indirectly affect LMO4, a transcriptional regulator involved in cellular differentiation processes. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Cyclopamine inhibits the Hedgehog (Hh) signaling pathway by targeting the Smoothened (SMO) receptor. As the Hh pathway is significant in embryonic development and cell differentiation, its inhibition can indirectly modulate LMO4 function. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation by blocking IκBα phosphorylation. As the NF-κB pathway is involved in inflammation, immune response, and cell survival, inhibition can indirectly modulate LMO4 activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 inhibits the TGF-β type I receptor ALK5 kinase, affecting processes like proliferation, differentiation, and apoptosis. LMO4, involved in cell differentiation, can be indirectly influenced by disruptions in TGF-β signaling. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
AICAR activates AMP-activated protein kinase (AMPK), regulating cellular energy homeostasis. LMO4, involved in cellular metabolic processes, can be indirectly affected by AMPK pathway modulation. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil, a calcium channel blocker, inhibits L-type calcium channels. Calcium signaling, crucial for processes including proliferation and differentiation, indirectly modulates LMO4's function through its disruption. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Go6983 inhibits protein kinase C (PKC), which plays a role in differentiation and proliferation. Inhibition of PKC can thus indirectly affect LMO4's role in these processes. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride (LiCl) inhibits glycogen synthase kinase-3 beta (GSK-3β). Inhibition of GSK-3β, involved in processes including Wnt/β-Catenin signaling, can indirectly modulate LMO4 activity, particularly in cell proliferation and differentiation pathways. | ||||||